Phase II/III Randomized Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial ALS Amyotrophic Lateral Sclerosis (ALS).
Phase of Trial: Phase II/III
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Arimoclomol (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Jan 2018 According to an Orphazyme media release, results were published in in the peer-reviewed clinical journal Neurology.
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.